Respiratory Committee

Chair: Tom Stinchcombe, M.D.
Vice-Chairs: Dennis Wigle (Surgery)
            Steven Schild (Radiation Oncology)
            Stephen Graziano (Correlative Science)

1. Committee overview, and protocol accrual – Chair and Xiaofei Wang

2. Concepts in development

   1. Brain metastases in mutation negative patients: chemotherapy + pembrolizumab
      Mark Awad

   2. Extensive stage SCLC- Jacob Sands

   3. Lurbinecten in maintenance trial in ES-SCLC Jeff Petty

   4. Colchicine Anti-inflammatory Tumor Outcomes Study – Early Lung Cancer
      (CANTOS-ELC): A Randomized Double-Blind Placebo Controlled Trial of Adjuvant
      Colchicine for Non-Metastatic Stage 1A2, IA3, and IB Lung Cancer

3. NCI Lung-MAP Jyoti Patel

   1. Entinostat + pembrolizumab- Jyoti Patel

   2. Randomized Phase Ib/II Study of Docetaxel and CB-839 vs Docetaxel ±
      Ramucirumab in Patients with NSCLC Harboring KRAS and Co-Occurring
      Mutations in LKB1 or KEAP1 Genes or Both Muhammad Furqan


5. Stage IV Non-Small Cell Lung Cancer
DRAFT AGENDA

1. A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta, Lyudmila Bazhenova

2. AFT-42: Nivolumab for patients with compromised organ function – Becca Heist, Phil Stella

6. Stage III Non-Small Cell Lung Cancer
   1. AFT-16: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic
   2. AFT-46: Chemo-immunotherapy for operable stage III NSCLC Linda Martin, Jyoti Patel

7. Early Stage Non-Small Cell Lung Cancer and Surgical Studies - Dennis Wigle
   1. A151216/081105 - ALCHEMIST - Personalized Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer – Geoffrey Oxnard, Ramaswamy Govindan, Dennis Wigle, Sumithra Mandrekar
   2. Adjuvant chemotherapy alone or in combination with pembrolizumab - Jacob Sands

8. Small Cell Lung Cancer
   1. CALGB 30610: Limited Stage Intergroup Trial – Jeffrey Bogart and Greg Masters
   2. NRG 003: ChemoRT +/- atezolizumab - Helen Ross

9. Intergroup trials
   1. SWOG/NRG S1914: trial of immunotherapy followed by SBRT followed by immunotherapy Apar Ganti
   2. SWOG/Alliance S1827: PCI vs observation in ES-SCLC
   2. EGFR transformed SCLC - Vini Ernani
   3. E5142 Erin Bertino
   4. ALK biomarker trial - Tom Stinchcombe

10. Ongoing projects from other committees